Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes

The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin...

Full description

Saved in:
Bibliographic Details
Published inPatient preference and adherence Vol. 18; pp. 411 - 424
Main Authors Kerr, David, Rajpura, Jigar Ramesh, Namvar, Tarlan
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2024
Dove
Dove Medical Press
Subjects
diabetes mellitus
Diabetics
Dosage and administration
Drug therapy
Insulin
long-acting
Medical personnel
Original Research
patient preference
Personal preferences (Social sciences)
provider preference
Psychological aspects
Surveys
surveys and questionnaires
type 2
Type 2 diabetes
United States
patient preference
type 2
insulin
diabetes mellitus
provider preference
surveys and questionnaires
long-acting
Online AccessGet full text

Cover

Abstract The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options. In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors. Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin. Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.
AbstractList David Kerr,1 Jigar Ramesh Rajpura,2 Tarlan Namvar3 1Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA; 2Department of US Health Economic and Outcomes Research – Rare Disease Portfolio, Novo Nordisk Inc, Plainsboro, NJ, USA; 3Department of Evidence Synthesis and Value Assessment, Novo Nordisk Inc, Plainsboro, NJ, USACorrespondence: David Kerr, Diabetes Research and Digital Health Equity, Sutter Center for Health Systems Research, Santa Barbara, CA, USA, Tel +1 (805) 624-8688, Email david.kerr@sutterhealth.orgPurpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.Patients and Methods: In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.Results: Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users (“insulin experienced”) reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.Conclusion: Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. Keywords: diabetes mellitus, type 2, insulin, long-acting, surveys and questionnaires, patient preference, provider preference
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/yPQljy98UFw Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition.
Purpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options. Patients and Methods: In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naive and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors. Results: Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin. Conclusion: Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations. Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition. Keywords: diabetes mellitus, type 2, insulin, long-acting, surveys and questionnaires, patient preference, provider preference
The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options. In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors. Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin. Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.
PurposeThe global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.Patients and MethodsIn a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.ResultsMost respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.ConclusionDiscussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.
Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or sugar, that is broken down in the bloodstream. Many people with T2D have to take insulin to help their bodies manage their blood sugar effectively. We aimed to find out what people with T2D and healthcare providers (HCPs) think about a new type of basal insulin that only needs to be taken once a week, as compared to current basal insulins that are taken every day. We found that most people with T2D (91%) and HCPs (89%) would prefer a once-weekly insulin rather than another type of basal insulin. People with T2D currently taking insulin were also more confident that a once-weekly insulin could help control their blood sugar. Many people who are already using basal insulin (88%) said they would ask their HCP about a once-weekly insulin. HCPs said they were willing to educate patients about a once-weekly insulin (85%). This study shows that it is important for people with T2D and their HCPs to discuss what type of insulin is best for them, including the type of insulin and how often it is taken. Sharing preferences about medication options may be helpful in reducing the overall impact of the condition.
Audience Academic
Author Kerr, David
Rajpura, Jigar Ramesh
Namvar, Tarlan
Author_xml – sequence: 1
  givenname: David
  surname: Kerr
  fullname: Kerr, David
  organization: Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA
– sequence: 2
  givenname: Jigar Ramesh
  surname: Rajpura
  fullname: Rajpura, Jigar Ramesh
  organization: Department of US Health Economic and Outcomes Research - Rare Disease Portfolio, Novo Nordisk Inc, Plainsboro, NJ, USA
– sequence: 3
  givenname: Tarlan
  surname: Namvar
  fullname: Namvar, Tarlan
  organization: Department of Evidence Synthesis and Value Assessment, Novo Nordisk Inc, Plainsboro, NJ, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38375061$$D View this record in MEDLINE/PubMed
BookMark eNptkl2LEzEUhgdZcT_0ynsJCCJI6-RjMjNXS91dtbCwBVf0LmQyJ21qmtQk06X_3qytSwuSwDmcPHnJyXnPixPnHRTFa1yOCWb1x9lsMv7GKK9Y-aw4w7iuR03T_jw5yE-L8xiXZckpJ_hFcUobWlclx2fF8mYj7SCTcXM0ywFcQtL1aBb8xvQQcgIaAjgFEWkfkER3OR_9APhlt-iTjNKiqYuDNQ7lPekHmyJ6MGmB7rdrQARdG9lBgviyeK6ljfBqHy-K759v7q--jm7vvkyvJrcjVTGeRrpXrFFYNpqXvAOiqMKsqlmvQBKmeUOV7DgjUPNaatYBsA4ryjrJGeYtoxfFdKfbe7kU62BWMmyFl0b8LfgwFzIkoywIzTGWfdVRRSkjLWsrovu2LoFUrca8z1qXO6310K0gP8GlIO2R6PGJMwsx9xuBy6auMK-zwvu9QvC_B4hJrExUYK104IcoSEuaJo8O04y-3aFzmd9mnPZZUj3iYlI3WYvk5jM1_g-VVw8ro7I1tMn1owvvDi4sQNq0iN4OyXgXj8EPO1AFH2Oe-1OfuBSPVhPZamJvtUy_OfyaJ_aft-gfgjnPGg
CitedBy_id crossref_primary_10_3390_jcm13072113
Cites_doi 10.2337/dc23-S009
10.1016/j.eprac.2022.04.006
10.1186/s12874-021-01209-w
10.1111/dom.13132
10.1136/bmjgh-2022-010942
10.2991/jegh.k.191028.001
10.1089/dia.2021.0164
10.2147/ppa.S101821
10.1136/postgradmedj-2019-137190
10.2337/dc21-2396
10.2337/dc22-0242
10.2147/ppa.S87935
10.1016/j.clinthera.2016.09.020
10.1016/S2213-8587(18)30051-2
10.1007/s13300-018-0421-5
10.3389/fendo.2019.00536
10.2147/ppa.S194598
10.1001/jama.2023.11313
10.2147/ppa.S114619
10.2337/dc17-1144
10.2337/diacare.28.11.2673
10.1177/1932296820973185
10.1111/dom.14871
10.2337/diaspect.29.3.166
10.2337/diaclin.22.3.147
10.3389/fpubh.2021.782964
10.1016/j.jval.2020.01.023
10.1136/bmjdrc-2020-001926
10.1177/1932296820963630
10.1080/03007995.2016.1253553
10.1016/j.amjmed.2008.03.022
10.1111/dom.14244
10.1016/s2213-8587(23)00093-1
10.1080/03007995.2022.2125259
10.2147/ppa.S204111
10.1001/jama.2023.2854
10.1185/03007995.2012.743458
10.1007/s13300-021-01097-9
10.1016/j.ijcard.2022.09.009
10.1016/j.dsx.2022.102615
10.1136/bmj.310.6972.83
ContentType Journal Article
Copyright 2024 Kerr et al.
COPYRIGHT 2024 Dove Medical Press Limited
2024 Kerr et al. 2024 Kerr et al.
Copyright_xml – notice: 2024 Kerr et al.
– notice: COPYRIGHT 2024 Dove Medical Press Limited
– notice: 2024 Kerr et al. 2024 Kerr et al.
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.2147/PPA.S436540
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList



PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Kerr et al
EISSN 1177-889X
EndPage 424
ExternalDocumentID oai_doaj_org_article_f611ad5b3c334294952fd970e259f16d
A786732683
10_2147_PPA_S436540
38375061
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
123
29O
2WC
53G
5VS
7RV
8C1
8FI
8FJ
8G5
ABDBF
ABUWG
ACGFO
ADBBV
ADRAZ
AENEX
AFKRA
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BKEYQ
BPHCQ
BVXVI
CCPQU
DIK
DWQXO
E3Z
EBD
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M2O
M48
MK0
M~E
NAPCQ
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
TUS
UKHRP
VDV
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c546t-fdc48c1a8f606be2c3c14574dcea24f683cab642e767af4bee4b1c34ba6416943
IEDL.DBID RPM
ISSN 1177-889X
IngestDate Fri Oct 04 13:06:19 EDT 2024
Tue Sep 17 21:29:32 EDT 2024
Fri Aug 16 21:43:15 EDT 2024
Wed Mar 27 18:02:03 EDT 2024
Tue Mar 26 04:58:01 EDT 2024
Tue Aug 20 22:15:07 EDT 2024
Fri Aug 23 02:52:51 EDT 2024
Fri Oct 18 08:36:10 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords patient preference
type 2
insulin
diabetes mellitus
provider preference
surveys and questionnaires
long-acting
Language English
License 2024 Kerr et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c546t-fdc48c1a8f606be2c3c14574dcea24f683cab642e767af4bee4b1c34ba6416943
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875167/
PMID 38375061
PQID 2928854013
PQPubID 23479
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_f611ad5b3c334294952fd970e259f16d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10875167
proquest_miscellaneous_2928854013
gale_infotracmisc_A786732683
gale_infotracacademiconefile_A786732683
gale_healthsolutions_A786732683
crossref_primary_10_2147_PPA_S436540
pubmed_primary_38375061
PublicationCentury 2000
PublicationDate 2024-01-01
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-01
  day: 01
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
PublicationTitle Patient preference and adherence
PublicationTitleAlternate Patient Prefer Adherence
PublicationYear 2024
Publisher Dove Medical Press Limited
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Dove
– name: Dove Medical Press
References Robinson (ref18) 2021; 23
King (ref23) 2022; 38
Boye (ref20) 2021; 23
Noben (ref25) 2020; 97
ref2
Philis-Tsimikas (ref31) 2023; 25
Wei (ref44) 2019; 10
Harris (ref12) 2010; 56
van Heuckelum (ref28) 2019; 13
Seng (ref40) 2021; 21
Stewart (ref27) 2016; 10
Liu (ref35) 2023; 8
Khan (ref1) 2020; 10
Polonsky (ref9) 2004; 22
Savarese (ref33) 2023; 371
Boye (ref21) 2021; 12
ElSayed (ref5) 2023; 46
Kerr (ref14) 2022; 28
Blumer (ref11) 2017; 39
Yavuz (ref6) 2015; 9
Russell-Jones (ref10) 2018; 20
Kerr (ref13) 2020; 14
Perez-Nieves (ref15) 2018; 9
Tomaszewski (ref24) 2019; 13
ref43
Rolla (ref19) 2008; 121
Singh (ref32) 2022; 16
Klonoff (ref37) 2021; 15
Laiteerapong (ref4) 2019; 42
Flood (ref22) 2017; 33
Huang (ref36) 2021; 9
Peyrot (ref8) 2005; 28
Brod (ref17) 2012; 28
Lingvay (ref29) 2023; 330
Ahlqvist (ref41) 2018; 6
ref7
Sarbacker (ref16) 2016; 29
Davis (ref42) 2022; 45
Philis-Tsimikas (ref30) 2023; 11
Fang (ref3) 2022; 45
Rutten (ref38) 2020; 8
Pagidipati (ref39) 2023; 329
Ozdemir (ref34) 2020; 23
Garcia-Dominguez (ref26) 2016; 10
References_xml – volume: 46
  start-page: S140
  year: 2023
  ident: ref5
  publication-title: Diabetes Care
  doi: 10.2337/dc23-S009
  contributor:
    fullname: ElSayed
– volume: 28
  start-page: 811
  year: 2022
  ident: ref14
  publication-title: Endocr Pract
  doi: 10.1016/j.eprac.2022.04.006
  contributor:
    fullname: Kerr
– volume: 21
  start-page: 49
  year: 2021
  ident: ref40
  publication-title: BMC Med. Res. Method.
  doi: 10.1186/s12874-021-01209-w
  contributor:
    fullname: Seng
– volume: 20
  start-page: 488
  year: 2018
  ident: ref10
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.13132
  contributor:
    fullname: Russell-Jones
– volume: 8
  start-page: 56
  year: 2023
  ident: ref35
  publication-title: BMJ Glob Health
  doi: 10.1136/bmjgh-2022-010942
  contributor:
    fullname: Liu
– ident: ref43
– volume: 10
  start-page: 107
  year: 2020
  ident: ref1
  publication-title: J Epidemiol Glob Health
  doi: 10.2991/jegh.k.191028.001
  contributor:
    fullname: Khan
– volume: 23
  start-page: 844
  year: 2021
  ident: ref18
  publication-title: Diabetes Technol. Ther.
  doi: 10.1089/dia.2021.0164
  contributor:
    fullname: Robinson
– volume: 10
  start-page: 1385
  year: 2016
  ident: ref27
  publication-title: Patient Prefer Adherence
  doi: 10.2147/ppa.S101821
  contributor:
    fullname: Stewart
– volume: 97
  start-page: 515
  year: 2020
  ident: ref25
  publication-title: Postgraduate Medi J
  doi: 10.1136/postgradmedj-2019-137190
  contributor:
    fullname: Noben
– volume: 45
  start-page: 484
  year: 2022
  ident: ref42
  publication-title: Diabetes Care
  doi: 10.2337/dc21-2396
  contributor:
    fullname: Davis
– volume: 45
  start-page: 1994
  year: 2022
  ident: ref3
  publication-title: Diabetes Care
  doi: 10.2337/dc22-0242
  contributor:
    fullname: Fang
– volume: 9
  start-page: 1225
  year: 2015
  ident: ref6
  publication-title: Patient Prefer Adherence
  doi: 10.2147/ppa.S87935
  contributor:
    fullname: Yavuz
– volume: 39
  start-page: S1
  year: 2017
  ident: ref11
  publication-title: Clin. Ther.
  doi: 10.1016/j.clinthera.2016.09.020
  contributor:
    fullname: Blumer
– volume: 6
  start-page: 361
  year: 2018
  ident: ref41
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(18)30051-2
  contributor:
    fullname: Ahlqvist
– volume: 9
  start-page: 1099
  year: 2018
  ident: ref15
  publication-title: Diabetes Ther
  doi: 10.1007/s13300-018-0421-5
  contributor:
    fullname: Perez-Nieves
– volume: 56
  start-page: e418
  year: 2010
  ident: ref12
  publication-title: Can Fam Physician
  contributor:
    fullname: Harris
– volume: 10
  start-page: 536
  year: 2019
  ident: ref44
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2019.00536
  contributor:
    fullname: Wei
– volume: 13
  start-page: 761
  year: 2019
  ident: ref24
  publication-title: Patient Prefer Adherence
  doi: 10.2147/ppa.S194598
  contributor:
    fullname: Tomaszewski
– volume: 330
  start-page: 228
  year: 2023
  ident: ref29
  publication-title: JAMA
  doi: 10.1001/jama.2023.11313
  contributor:
    fullname: Lingvay
– volume: 10
  start-page: 1945
  year: 2016
  ident: ref26
  publication-title: Patient Prefer Adherence
  doi: 10.2147/ppa.S114619
  contributor:
    fullname: Garcia-Dominguez
– ident: ref2
– volume: 42
  start-page: 416
  year: 2019
  ident: ref4
  publication-title: Diabetes Care
  doi: 10.2337/dc17-1144
  contributor:
    fullname: Laiteerapong
– volume: 28
  start-page: 2673
  year: 2005
  ident: ref8
  publication-title: Diabetes Care
  doi: 10.2337/diacare.28.11.2673
  contributor:
    fullname: Peyrot
– volume: 15
  start-page: 177
  year: 2021
  ident: ref37
  publication-title: J Diabetes Sci Technol
  doi: 10.1177/1932296820973185
  contributor:
    fullname: Klonoff
– volume: 25
  start-page: 331
  year: 2023
  ident: ref31
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.14871
  contributor:
    fullname: Philis-Tsimikas
– volume: 29
  start-page: 166
  year: 2016
  ident: ref16
  publication-title: Diabetes Spectr
  doi: 10.2337/diaspect.29.3.166
  contributor:
    fullname: Sarbacker
– volume: 22
  start-page: 147
  year: 2004
  ident: ref9
  publication-title: Clin Diabetes
  doi: 10.2337/diaclin.22.3.147
  contributor:
    fullname: Polonsky
– volume: 9
  start-page: 782964
  year: 2021
  ident: ref36
  publication-title: Front Public Health
  doi: 10.3389/fpubh.2021.782964
  contributor:
    fullname: Huang
– volume: 23
  start-page: 842
  year: 2020
  ident: ref34
  publication-title: Value Health
  doi: 10.1016/j.jval.2020.01.023
  contributor:
    fullname: Ozdemir
– volume: 8
  start-page: e001926
  year: 2020
  ident: ref38
  publication-title: BMJ Open Diabetes Res Care
  doi: 10.1136/bmjdrc-2020-001926
  contributor:
    fullname: Rutten
– volume: 14
  start-page: 1107
  year: 2020
  ident: ref13
  publication-title: J Diabetes Sci Technol
  doi: 10.1177/1932296820963630
  contributor:
    fullname: Kerr
– volume: 33
  start-page: 261
  year: 2017
  ident: ref22
  publication-title: Curr Med Res Opin
  doi: 10.1080/03007995.2016.1253553
  contributor:
    fullname: Flood
– volume: 121
  start-page: S9
  year: 2008
  ident: ref19
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2008.03.022
  contributor:
    fullname: Rolla
– volume: 23
  start-page: 508
  year: 2021
  ident: ref20
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.14244
  contributor:
    fullname: Boye
– volume: 11
  start-page: 414
  year: 2023
  ident: ref30
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/s2213-8587(23)00093-1
  contributor:
    fullname: Philis-Tsimikas
– volume: 38
  start-page: 1831
  year: 2022
  ident: ref23
  publication-title: Curr. Med. Res. Opin.
  doi: 10.1080/03007995.2022.2125259
  contributor:
    fullname: King
– volume: 13
  start-page: 1199
  year: 2019
  ident: ref28
  publication-title: Patient Prefer Adherence
  doi: 10.2147/ppa.S204111
  contributor:
    fullname: van Heuckelum
– volume: 329
  start-page: 1261
  year: 2023
  ident: ref39
  publication-title: JAMA
  doi: 10.1001/jama.2023.2854
  contributor:
    fullname: Pagidipati
– volume: 28
  start-page: 1933
  year: 2012
  ident: ref17
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007995.2012.743458
  contributor:
    fullname: Brod
– volume: 12
  start-page: 2387
  year: 2021
  ident: ref21
  publication-title: Diabetes Therapy
  doi: 10.1007/s13300-021-01097-9
  contributor:
    fullname: Boye
– volume: 371
  start-page: 526
  year: 2023
  ident: ref33
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2022.09.009
  contributor:
    fullname: Savarese
– volume: 16
  start-page: 102615
  year: 2022
  ident: ref32
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2022.102615
  contributor:
    fullname: Singh
– ident: ref7
  doi: 10.1136/bmj.310.6972.83
SSID ssj0063621
Score 2.376149
Snippet The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess...
Purpose: The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought...
Plain Language Summary: Type 2 diabetes (T2D) is a medical condition where the body has difficulty managing insulin, a hormone used to control glucose, or...
PurposeThe global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to...
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/yPQljy98UFw Type 2 diabetes...
David Kerr,1 Jigar Ramesh Rajpura,2 Tarlan Namvar3 1Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA; 2Department of US Health...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 411
SubjectTerms diabetes mellitus
Diabetics
Dosage and administration
Drug therapy
Insulin
long-acting
Medical personnel
Original Research
patient preference
Personal preferences (Social sciences)
provider preference
Psychological aspects
Surveys
surveys and questionnaires
type 2
Type 2 diabetes
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxQxFA7Sg3gRa_0xtmoKBU9jm8mPyRy30tIWqgta6C28ZBKth6k42__f9ybZZQcPXoRdCJvsMMmXvHwvefnC2FEEgNSHjrb-U61E0LW3cFILAWCAFNamHd3rz-biRl3d6tutq74oJizLA-eGO04G_9ZrL4OUaDuRzzep79qTiLw9CdNP1lfotTOVbbBBsyzyaTy6h-d4uVx8_KqkmdY4tuafSab_b2O8NRvNIyW3pp7zZ-xp4Yx8kd91lz2Kw3P2-Lrsiu-xn2dFsnv4zpdZJ5XD0PNlOWWHibWc7MiRpHLgXzBdZzV9fgojPv0yB6Vz_CxIk2PktETLyU_lDS-BM-MLdnN-9u3TRV3uUKiDVmZVIw7KBgE2oafiYxNkEEq3CmsEjUrGygAefZDYmhaS8jEqL4JUHgxStU7Jl2xnuB_ia8ZDp2OU4HWSSYHsrE34Naa3IFvbtRU7Wres-5WlMhy6GASAQwBcAaBip9TqmyKkbz39gKi7grr7F-oVe0-YuXxYdDNK3aK1pkVGamXFPkwlaJwidAHKcQOsCylezUoezEri-Aqz7MN1v3CURUFpQ7x_GF3TNdZqclAr9ir3k02tyPHXyJUqZmc9aFbtec5w92OS9xZ0yYAw7Zv_0VD77EmDNCwvGh2wndXvh_gWadTKv5tGzB8ZLBqU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEA_nCeLL4bfVUyMc-NTz0nz2QWRP7jiF1QVd2LcwTZM7Rbrndg_0v3fSZJerCkILpUkLk5lJZjKT3xBy4AEgtK6Oof9QCuZk2Rg4KhkDUBAR1oaI7vSjOpuLDwu52CGbYpx5APt_unaxntR89f3w549fb1Hh38Q0Zib069lscvhZcIXGxw1ysxJcRFGfim04QeEszVKVFZySTb1IB_X-_Hi0NA0I_n_P09cWqnES5bVV6fQO2cvmJJ0k_t8lO767R25Nc8D8Pvl2ktG8u3M6SxCqFLqWzvIBPHzYIM32FO1XCvQTPpcJaJ8eQ49_f5_y1SlekwjX0dO4e0ujC0srmnNq-gdkfnry5d1ZmcsrlE4KtS6RRcI4BiagE9P4ynHHhNQCKYJKBGW4gwbdE6-VhiAa70XDHBcNKLTiasEfkt1u2fnHhLpaes-hkYEHAbw2JuCtVGuAa1PrghxsRtZeJhQNi95HZIBFBtjMgIIcx1HfdonQ18OL5ercZk2yQaEctbLhjnNcTNHBq0Jb6yOPjlxgqi3Ii8gzm86RbhXYTrRRGo1VwwvyaugRhQpZ5yCfREBaIhjWqOf-qCeqnhs1v9zIhY1NMV-t88ur3lZ1ZYyMvmtBHiU52VIV9wQkmlEFMSMJGpE9bum-XgzI3yzWH2BKP_kvjU_J7QrNr7RZtE9216sr_wzNp3XzfFCN33vFF94
  priority: 102
  providerName: Scholars Portal
Title Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
URI https://www.ncbi.nlm.nih.gov/pubmed/38375061
https://search.proquest.com/docview/2928854013
https://pubmed.ncbi.nlm.nih.gov/PMC10875167
https://doaj.org/article/f611ad5b3c334294952fd970e259f16d
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED6aDsZexn7PW5dpUNiTk8iSJfkxCSnZIJ3ZVuiejCxLbcfqlDr9_3ey7BCzt4EtjCUbS3eS7pPuPgOcWq21q0zmt_5dzKlJ41LpWUyp1kJ7hrV2R3dzLtYX_OtlenkEoo-FaZ32TXkzqf_cTuqb69a38u7WTHs_sWm-WVJPw06FnI5gJBnrMXoYfwUOyTRE4vl_8EzzfD75wZlo1zcO5p6Wov_fgfhgJhp6SR5MO2fP4GlnL5J5-K7ncGTrF_B40-2Iv4Tfq46uu74ieeBIJbquSN5F2OFFTyXbEDRQiSbf8DoOTPpkoRt8-5fgkE7wmHs-job45VniMSpJSOc007yCi7PVz-U67v6fEJuUi12MMuDKUK0copTSJoYZylPJsUY64U4oZnSJ-MNKIbXjpbW8pIbxUgs00zLOXsNxva3tWyAmS61lukwdc1yzTCmHpxCV0kyqTEZw2rdscRdoMgqEF14ABQqg6AQQwcK3-r6I57Zub2zvr4pOwoUTqChVWjLDGM6WiOASV2VyZhGpOSqqCD56mRUhUHTfQ4u5VEKiNapYBJ_bEr6PouiM7kINsC6e7WpQ8mRQEvuWGWR_6vWi8FneIa2224emSLJEqdSD0wjeBD3Z18qD_hTtpAjUQIMG1R7moKa31N69Zr_7_0ffw5MEDa-wTHQCx7v7B_sBDaddOYbR7NcaU7WkY3i0WJ3n38ftIgSmG67GbT_6C2fEH4M
link.rule.ids 230,315,733,786,790,870,891,2115,24346,27955,27956,33300,33778,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o9AoUaqxCm7Tew4znFbtdpCt0SiFb1ZtmOXtjRbNbsXfj3jOFlt4ARSIlmxE8WeGc-MPfMZYMcqpVxlCr_172KWmCzWQu3GSaIUVx5hrd3RnZ3w6Rn7fJ6dbwDvc2HaoH2jL0f1z5tRffmjja28vTHjPk5sXM72Ew_DnvB8fA_uo8CmWe-lhxmY46SchFw8fwrPuCwno2-M8naFY037tCD9f0_Fa7poGCe5pngOn8D3_pdDvMn1aLnQI_PrDzTHf-_TU3jc2aJkEuqfwYatn8ODWbfb_gKuDjoo8PqClAF_lai6ImWXvYeFHqa2IWj8EkW-YjkOKP1kTzX49aMQ7E7wmnisj4b4pV_i_V-Ski4gp3kJZ4cHp_vTuDubITYZ44sY6cuESZRw6AFpmxpqEpblDMdKpcxxQY3S6NvYnOfKMW0t04mhTCuOJmDB6CvYrOe1fQPEFJm1VOnMUccULYRweHNeCUVzUeQR7PQ0k7cBgkOi6-JJK5G0siNtBHuenqsmHje7fTC_u5DdSEvHkQmrTFNDKWpi9A5TVxX5rkUv0CW8imDbc4MMSagr6ZeTXPAcLV1BI_jUtvDyj0xhVJfGgH3xSFqDlluDlii3ZlD9sec46at8sFtt58tGpkUqROYd3wheBw5c9covKGRog0UgBrw56PawBjmuhQ3vOezt_7-6DQ-np7NjeXx08uUdPErRwAvLUVuwubhb2vdooC30h1YafwMV_jyF
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3o9AoUaqxClJEzuOc9yWrlpgSySoVImDZTt2aUuzq2b3wq9nHDurDdwqJVIUT6LYMx7P2J-_ILRnpJS20ZVb-rcxzXQRKy734yyTkknHsNav6M5O2fEZ_XxenAdUZRdgla1Wl0n7-yZpL3_12MrFjU4HnFhazw4zR8OesTJdNDa9jx5Ap83LIVP3XpiBY878fjz3J560rifJd0pYP8uxMQL1RP3_u-ON8WiMldwYfKaP0c_hsz3m5DpZLVWi__zD6Hi3ej1Bj0JMiide5im6Z9pnaHsWVt2fo6ujQAneXuDa87Bi2Ta4Drv44GKgq-0wBMFY4m9wHXu2fnwgO3j7iQe9YzgmjvOjw24KGLs8GOc4AHO6F-hsevTj8DgO_2iIdUHZMgY9U64zyS1kQsrkmuiMFiWF9pI5tYwTLRXkOKZkpbRUGUNVpglVkkEoWFHyEm2189a8RlhXhTFEqsISSyWpOLdwMtZwSUpelRHaG_QmFp6KQ0AK49QrQL0iqDdCB06naxHHn93fmN9eiNDawjIwxqZQRBMCIzJkibltqnLfQDZoM9ZEaNdZhPCbUddeQExKzkqIeDmJ0MdewvkBMAwtw3YGqItj1BpJ7owkof_qUfGHweqEK3Kgt9bMV53Iq5zzwiXAEXrlrXBdKzexUEAsFiE-ss9RtcclYHU9ffhgZW_u_ugu2q4_TcXXk9Mvb9HDHOI8Pyu1g7aWtyvzDuK0pXrfd8i_6xU_BQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+Patient+and+Provider+Preferences+for+a+Once-Weekly+Basal+Insulin+in+Adults+with+Type+2+Diabetes&rft.jtitle=Patient+preference+and+adherence&rft.au=Namvar%2C+Tarlan&rft.au=Kerr%2C+David&rft.au=Ramesh+Rajpura%2C+Jigar&rft.date=2024-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1177-889X&rft.eissn=1177-889X&rft.volume=18&rft.spage=411&rft_id=info:doi/10.2147%2FPPA.S436540&rft.externalDBID=n%2Fa&rft.externalDocID=A786732683
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-889X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-889X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-889X&client=summon